TY  - JOUR
AB  - Acute myeloid leukemia is a group of metabolic heterogeneous cancers, of which the long-term overall survival is still poor, especially in elderly patients. Targeting metabolic reprogramming in leukemic cells is becoming a promising strategy. The aim of our research was to explore the relation of genetic mutations with the metabolic phenotype and potential therapeutics to target metabolic pathway dependence. We confirmed the metabolic heterogeneity in AML cell lines and found the high dependence on oxidative phosphorylation in MLL/AF9 AML cells. Metformin could significantly repress the proliferation of MLL/AF9 AML cells by inhibiting oxidative phosphorylation.
AU  - Liu, Longlong
AU  - Patnana, Pradeep Kumar
AU  - Xie, Xiaoqing
AU  - Frank, Daria
AU  - Nimmagadda, Subbaiah Chary
AU  - Rosemann, Annegret
AU  - Liebmann, Marie
AU  - Klotz, Luisa Hildegard
AU  - Opalka, Bertram
AU  - Khandanpour, Cyrus
DA  - 2022-01-19
DO  - 10.17879/84069426952
KW  - heterogeneity
KW  - OXPHOS
KW  - MLL/AF9
KW  - metformin
LA  - eng
N1  - Cancers 14 (2022) 3, 486, 1-12
N1  - Finanziert durch den Open-Access-Publikationsfonds der Westfälischen Wilhelms-Universität Münster (WWU Münster).
PY  - 2022-01-19
TI  - High Metabolic Dependence on Oxidative Phosphorylation Drives Sensitivity to Metformin Treatment in MLL/AF9 Acute Myeloid Leukemia
UR  - https://nbn-resolving.org/urn:nbn:de:hbz:6-74069412000
Y2  - 2024-11-22T07:59:45
ER  -